DCC-2618

Modify Date: 2024-01-03 08:12:36

DCC-2618 structure	Common Name	DCC-2618
	CAS Number	1442472-39-0	Molecular Weight	510.36
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₂₁BrFN₅O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of DCC-2618

Ripretinib (DCC-2618) is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.

Name	DCC-2618

Description	Ripretinib (DCC-2618) is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit Research Areas >> Cancer
Target	PDGFRA KIT
In Vitro	Ripretinib is a pan-KIT and PDGFRA inhibitor, shows cytotoxic activity against gastrointestinal stromal tumors[1]. Ripretinib suppresses phosphorylation of KIT and decreases the expression of phosphosphorylated (p)STAT5, pAKT and pERK1/2 in neoplastic mast cells. Ripretinib inhibits the growth of ROSAKIT K509I cells with an IC50 of 34 ± 10 nM, and also induces apoptosis in these cells. Ripretinib (0.1-1.0 μM) inhibits IgE-dependent histamine release from basophils and spontaneous tryptase release from neoplastic mast cells, and also counteracts growth and survival of leukemic monocytes and blast cells at 0.01-5 μM[2].
References	[1]. BLU-285, DCC-2618 Show Activity against GIST. Cancer Discov. 2017 Feb;7(2):121-122. [2]. Schneeweiss M, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809.

Molecular Formula	C₂₄H₂₁BrFN₅O₂
Molecular Weight	510.36
Storage condition	-20℃

DC Chemicals Limited
China
Product Name: Ripretinib (DCC-2618)
Price: $500.0/100mg $900.0/250mg $1800.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Get all suppliers and price by the below link:

DCC-2618 suppliers

Price: $350/5mg

Reference only. check more DCC-2618 price